PMID- 9827713
OWN - NLM
STAT- MEDLINE
DCOM- 19981201
LR  - 20190620
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 83
IP  - 10
DP  - 1998 Nov 15
TI  - High levels of hepatocyte growth factor/scatter factor in diffuse-type 
      bronchioloalveolar cell carcinoma.
PG  - 2091-8
AB  - BACKGROUND: Hepatocyte growth factor/scatter factor (HGF/SF) is a potent mitogen 
      for various neoplastic cells, including neoplastic bronchial epithelia. METHODS: 
      Immunoreactive hepatocyte growth factor/scatter factor (HGF/SF) was measured in 
      extracts prepared from 129 nonsmall cell lung carcinoma (NSCLC) specimens, using 
      an enzyme-linked immunosorbent assay. These specimens represented 5 cases of 
      solitary/localized bronchioloalveolar cell carcinoma (BAC), 4 cases of 
      diffuse/infiltrative BAC, 90 cases of non-BAC adenocarcinoma, 25 cases of 
      squamous cell carcinoma, and 5 cases of large cell carcinoma. RESULTS: The mean 
      concentration of immunoreactive HGF/SF was more than 19-fold higher in tissue 
      extracts from diffuse-type BAG (265.0 +/- 110.2 ng/100 mg protein) than in those 
      from solitary-type BAC (13.9 +/- 15.9, P < 0.005), non-BAC adenocarcinoma (13.8 
      +/- 14.9, P < 0.001), squamous cell carcinoma (13.2 +/- 14.4, P < 0.001), or 
      large cell carcinoma (11.2 +/- 6.5, P < 0.005). When immunohistochemical staining 
      for HGF/SF was performed, intense HGF/SF staining was uniformly observed in 
      diffuse-type BAC tumor cells, but not in solitary-type BAC. CONCLUSIONS: Although 
      BAC is included as a subtype of adenocarcinoma in the World Health Organization 
      classification, diffuse-type BAC should be considered a distinct biologic entity, 
      at least in terms of HGF/SF expression, from solitary-type BAC or non-BAC 
      adenocarcinoma. In addition, the solitary and diffuse forms of BAC are known to 
      be associated with different prognoses; for the latter, the prognosis is much 
      poorer than for the former. The results of this study may at least partly explain 
      this difference in prognosis.
FAU - Yamashita, J
AU  - Yamashita J
AD  - Department of Surgery II, Kumamoto University School of Medicine, Japan.
FAU - Ogawa, M
AU  - Ogawa M
FAU - Nakano, S
AU  - Nakano S
FAU - Okabe, K
AU  - Okabe K
FAU - Abe, M
AU  - Abe M
FAU - Iwasaki, A
AU  - Iwasaki A
FAU - Kuwahara, M
AU  - Kuwahara M
FAU - Yoshinaga, Y
AU  - Yoshinaga Y
FAU - Shirakusa, T
AU  - Shirakusa T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Neoplasm Proteins)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
SB  - IM
MH  - Adenocarcinoma/chemistry
MH  - Adenocarcinoma, Bronchiolo-Alveolar/*chemistry
MH  - Aged
MH  - Carcinoma, Large Cell/chemistry
MH  - Carcinoma, Squamous Cell/chemistry
MH  - Female
MH  - Hepatocyte Growth Factor/*analysis
MH  - Humans
MH  - Lung Neoplasms/*chemistry
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Proteins/*analysis
EDAT- 1998/11/25 03:02
MHDA- 2000/06/20 09:00
CRDT- 1998/11/25 03:02
PHST- 1998/11/25 03:02 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1998/11/25 03:02 [entrez]
AID - 10.1002/(SICI)1097-0142(19981115)83:10<2091::AID-CNCR7>3.0.CO;2-E [pii]
AID - 10.1002/(sici)1097-0142(19981115)83:10<2091::aid-cncr7>3.0.co;2-e [doi]
PST - ppublish
SO  - Cancer. 1998 Nov 15;83(10):2091-8. doi: 
      10.1002/(sici)1097-0142(19981115)83:10<2091::aid-cncr7>3.0.co;2-e.